Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes

Paul Rj Ames, Alfredo Ortiz-Cadenas, Ignacio Garcia-De La Torre, Arnulfo Nava, Aldo Oregon-Miranda, Joana R. Batuca, Kazuo Kojima, Luis R. Lopez, Eiji Matsuura

Research output: Contribution to journalArticle

8 Citations (Scopus)


Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p<0.001). The decrease was statistically independent from the decrements of mean cholesterol, LDL and triglyceride concentrations (p<0.001) but probably dependent on the decrement of nitrate (p<0.001). Conclusion In type 2 diabetes, treatment with rosuvastatin was associated with a significant reduction of serum concentrations of oxLDL/β2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalBritish Journal of Diabetes and Vascular Disease
Issue number6
Publication statusPublished - Nov 1 2010



  • diabetes
  • oxidative stress
  • oxidised low-density lipoprotein/beta2- glycoprotein I

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this